Scarica l'app Stockscreener
33.36
3.31%
1.07
Dopo l'orario di chiusura:
33.03
-0.33
-0.99%
Precedente Chiudi:
$32.29
Aprire:
$32.31
Volume 24 ore:
359.92K
Relative Volume:
0.50
Capitalizzazione di mercato:
$2.59B
Reddito:
$688.00K
Utile/perdita netta:
$-170.19M
Rapporto P/E:
-10.94
EPS:
-3.0495
Flusso di cassa netto:
$-154.68M
1 W Prestazione:
-1.10%
1M Prestazione:
+1.28%
6M Prestazione:
+87.52%
1 anno Prestazione:
+60.23%
Intervallo 1D:
$32.31
$33.77
Intervallo di 1 settimana:
$31.52
$35.06
Portata 52W:
$10.91
$35.31
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Nome
Spyre Therapeutics Inc
Settore
Industria
Telefono
(617) 651-5940
Indirizzo
221 CRESCENT STREET, WALTHAM
Confronta SYRE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
33.36 | 2.51B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-12-17 | Iniziato | Citigroup | Buy |
| 2025-09-26 | Iniziato | Deutsche Bank | Buy |
| 2025-04-08 | Iniziato | Leerink Partners | Outperform |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2024-09-04 | Iniziato | Wedbush | Outperform |
| 2024-07-16 | Iniziato | Evercore ISI | Outperform |
| 2024-05-02 | Iniziato | Robert W. Baird | Outperform |
| 2024-03-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-12-11 | Iniziato | Guggenheim | Buy |
| 2023-12-11 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2019-03-21 | Iniziato | JP Morgan | Overweight |
| 2018-09-04 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Iniziato | Evercore ISI | Outperform |
| 2018-03-14 | Reiterato | Needham | Buy |
Mostra tutto
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Trend Review: Is Spyre Therapeutics Incs ROIC above industry averagePrice Action & Weekly Top Performers Watchlists - baoquankhu1.vn
Is Spyre Therapeutics Incs ROIC above industry averageJuly 2025 Action & High Accuracy Buy Signal Tips - baoquankhu1.vn
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre’s new commercial chief granted 108K stock options at $34.09 - Stock Titan
Insider Buy: Can SYFPRA maintain sales growthAnalyst Upgrade & AI Forecast Swing Trade Picks - baoquankhu1.vn
Spyre Therapeutics, Inc. (SYRE) Stock Analysis: A Biotech Gem With 65% Upside Potential - directorstalkinterviews.com
Bull Run: Can Spyre Therapeutics Inc lead its sector in growth2025 Geopolitical Influence & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Aug Final Week: Is FORL a defensive stockChart Signals & Accurate Trade Setup Notifications - baoquankhu1.vn
Big Picture: How does Spyre Therapeutics Inc score in quality rankings2025 Price Action Summary & Verified Swing Trading Watchlists - baoquankhu1.vn
Spyre Therapeutics’ SPY002-091 Study: A Potential Game-Changer in Drug Development - MSN
Wall Street bullish on Spyre Therapeutics, Inc. (SYRE) with strong buy rating - MSN
Weekly Trades: Is FNGSs growth already priced inTrend Reversal & Growth Focused Entry Point Reports - baoquankhu1.vn
Spyre Therapeutics (SYRE) Valuation Check After Strong Recent Share Price Performance - Yahoo Finance
SYRE: BTIG Reiterates Buy Rating with $70 Price Target | SYRE St - GuruFocus
Spyre Therapeutics (NASDAQ:SYRE) Receives "Buy" Rating from BTIG Research - MarketBeat
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating - Insider Monkey
Spyre Therapeutics (NASDAQ:SYRE) Trading 7.7% HigherWhat's Next? - MarketBeat
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments By Investing.com - Investing.com Nigeria
Spyre Therapeutics Advances with Phase 1 Study of SPY002-072 - MSN
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments - Investing.com
Spyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership - TipRanks
Quarterly Risk: Is Spyre Therapeutics Inc a top pick in the sectorMarket Activity Summary & High Conviction Trade Alerts - baoquankhu1.vn
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts - TradingView — Track All Markets
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 - The Manila Times
Spyre Therapeutics IncSkyline Trial In UC Completes SPY001 Enrollment Ahead Of Schedule - TradingView
Six drug trials target colitis and arthritis, with first patient data in 2026 - Stock Titan
Spyre Therapeutics' CEO Sells 15,000 Shares - The Motley Fool
What technical charts say about OXYWS stockJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - moha.gov.vn
Sentiment Recap: Is Spyre Therapeutics Inc. stock cheap at current valuation2025 Pullback Review & Smart Investment Allocation Insights - Улправда
Spyre Therapeutics, Inc. (SYRE) Stock Analysis: Innovative Biotech with 86.51% Upside Potential - DirectorsTalk Interviews
Why Spyre Therapeutics Inc. stock is popular among millennials2025 Geopolitical Influence & Technical Entry and Exit Tips - Улправда
Why Spyre Therapeutics Inc. stock remains resilient2025 Market Overview & Verified Entry Point Detection - Улправда
Is Spyre Therapeutics Inc. stock a contrarian buy2025 Pullback Review & Entry and Exit Point Strategies - Улправда
Is Spyre Therapeutics Inc. stock positioned for digital transformationPortfolio Profit Report & Capital Efficient Trading Techniques - Улправда
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of “Buy” by Brokerages - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Brokerages - MarketBeat
Aeglea BioTherapeutics Announces Grants of Inducement Awards - Quantisnow
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock - MarketBeat
Turtle Cameron, CEO of Spyre Therapeutics, sells $460k in shares - Investing.com Canada
Institution Moves: Is Spyre Therapeutics Inc stock a contrarian buy2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn
Spyre Therapeutics stock drops as biotech slides — what SYRE investors watch next - TechStock²
Spyre Therapeutics stock slid 6.6% into the weekend — here’s what matters before Monday’s open - TechStock²
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5% – Time to Sell? - Defense World
Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus - TechStock²
Spyre Therapeutics stock sinks 7% today: what’s pressuring SYRE and what investors watch next - ts2.tech
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5%Time to Sell? - MarketBeat
Spyre Therapeutics (SYRE) Sees Significant Decline in Stock Value - GuruFocus
Spyre Therapeutics: Validated Targets, Optimized Delivery - Seeking Alpha
CapEx per share of Spyre Therapeutics, Inc – SWB:3920 - TradingView — Track All Markets
Spyre Therapeutics Slides Despite Bullish Long-Term Hopes - TipRanks
Street Watch: Is Spyre Therapeutics Inc stock a contrarian buyQuarterly Market Summary & Daily Entry Point Trade Alerts - moha.gov.vn
Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):